Up to 500,000 surgeries in the U.S. has been complicated by Surgical site infections (SSIs). This accounts for 1 million excess days of hospitalization and $1.6 billion in additional healthcare expenditure.

Intravenous prophylactic antibiotics have systemic distribution, which may limit bactericidal concentrations locally, with the risk of systemic adverse effects, including hypersensitivity reactions and renal toxicity. Topical antibiotics, by contrast, have the advantage of achieving high local concentrations at the surgical site, where contaminating pathogens are located, while minimizing systemic toxicity. Due to the increasing prevalence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA), which now accounts for as many as half of all SSIs, efficacy of topical vancomycin for reducing SSIs is being increasingly explored.

In our study, we seek to evaluate the benefits of topical vancomycin. We hypothesize that application of topical vancomycin during closure of craniotomy reduces the risk of surgical site infections.

Keywords: Craniotomy, Surgical site infection, Vancomycin

Topical use of Vancomycin in Craniotomy

In neurosurgery, surgical site infections are major cause of morbidity and mortality. It has been a significant burden in clinical practice, despite of best practices with or without use of antibiotics. Topical antibiotics are one potential method reducing the problem. In our study, we seek to evaluate the benefits of topical vancomycin. In this Institutional Review Board-approved retrospective observational study, patients who underwent neurosurgical intervention in Department of Neurological Surgery KMCTH enrolled retrospectively from October 1, 2014 to September 30, 2018. Patients in whom topical vancomycin powder applied intraoperatively for postoperative SSI prophylaxis and those without, comprising the vast majority of neurosurgical patients within the KMCTH, were examined. Patients presenting with infection, open wound, multiple scheduled surgeries, application of topical antibiotics other than vancomycin, or multiple antibiotics were excluded. Patients data were analyzed within the first 30 days after surgery. There were total 259 patients with 190 as control and 69 as cases. With all these surgeries undergone we had SSI in 5, 1.93% (p = <0.001) of emergency surgeries, where Vancomycin powder was not used. There were no surgical site infection in any of the cases where topical Vancomycin powder was used. Topical vancomycin is a safe, effective, and economical measure to prevent SSIs following craniotomy.
incidence of SSIs postoperatively. There is currently not much data assessing the efficacy of topical vancomycin among neurosurgical patients undergoing craniotomy, and a prospective, randomized clinical trial is needed. With this study we could identify, justify and thus eliminate important post-operative morbidity, the SSI in neurosurgery.

Materials and Method:

In this Institutional Review Board-approved study, patients who underwent neurosurgical intervention in Department of Neurological Surgery KMCTH were enrolled retrospectively from October 1, 2014 to September 30, 2018.

Patients were divided into two groups, with and without topical application of vancomycin powder. We used 1 gm of Vancomycin powder sprinkled equally all over the surgical area prior to closure of skin. Patients in whom topical vancomycin powder applied intraoperatively for postoperative SSI prophylaxis and those without (No Vancomycin group, NVG), comprising the vast majority of neurosurgical patients within the KMCTH, were examined. Patients presenting with infection, open wound, multiple scheduled surgeries, application of topical antibiotics other than vancomycin, or multiple antibiotics; were excluded. Data related to pre and post-operative antibiotic administration, surgical service, surgery scheduling, and postoperative infection were collected from the electronic and other medical record.

Data registration were done in the designated Performa, prepared for the study. Registration of baseline and clinical data were collected starting on admission in the hospital. Patients presenting in ER and NS OPD, who had been admitted and underwent neurosurgical intervention as routine and emergency surgery were identified and needful details collected.

Data was collected using a pre-designed questionnaire. These collected data were entered in SPSS data sheet, subjected for descriptive statistics, diagrams and the needful z test. Statistical analysis was done using SPSS computer software version 15.0. The p value of < 0.05 was taken as statistically significant.

Results:

There were total 259 patients with 190 as control and 69 as cases. The age ranges from 18 to 63 years with mean age of presentation being 40 years. Altogether 209 Males outnumbered 50 females. The most of the surgeries undergone were emergency (n = 167) with elective surgery being 92.

Among surgeries undertaken, they could be categorized as Trauma 76% (n = 196), vascular 15% (n = 39), tumor 7% (n = 18) and miscellaneous 18 (2%).
to proceed with further management and left hospital against medical advice. With this study known side effects associated with parenteral administration of vancomycin did not appear to occur when the drug is applied topically into a surgical wound.

Figure 3: Surgical site infection: (a) Intraoperative osteomyelitic bone with pathological fracture and bone resorption, (b) superior view of the skull bone removed, (c) inferior view of the skull bone removed.

Discussion:

“Certainly infections cannot be attributed to the intervention of the devil but must be laid at the surgeon’s door” Cushing. Surgical site infections (SSIs) is nightmare for every surgeon including neurosurgeons. It has been a significant burden in clinical practice, despite of best practices with or without use of antibiotics. Vancomycin powder has been applied to wounds easily, is inexpensive, and can achieve high local concentrations with low systemic levels.

SSIs after craniotomy complicate 2–5% of approximately 2 million procedures annually, triple the length of stay (LOS), and on average cost an additional $26,000 per case. As per published studies, incidence of SSIs in neurosurgery overall varies from 1 to 11%. Several types of wound infections can appear after a brain surgery including meningitis, epidural abscess, subdural empyema, brain abscess, and bone flap osteomyelitis. In this study, we present the first Nepali large institutional series of open craniotomy patients treated with topical vancomycin with the goal of preventing postoperative SSI.

There has been many investigations with protective beneficial effect of intrawound vancomycin in both instrumented and non-instrumented spine surgeries. It is important to note that topical vancomycin prevents S. aureus infection, the leading cause of SSIs. Ideally, these antibiotics would achieve minimal systemic absorption, a high local concentration, and have minimal local and systemic adverse event. In this study, among the infected cultures there were mixed growth of E. coli and Acinetobacter in 5.6% cases, causing deep infection. A similar benefit was demonstrated in cardiothoracic surgery when vancomycin paste was applied to the cut edges of the sternum during sternotomy closure.

In a recent large meta-analysis, risk factors associated with SSI following open craniotomies were identified and included other infection, number of previous operations, CSF leak, CSF drainage, duration of operation, venous sinus entry, ASA (American Society of Anesthesiologists) score > 2, sex (male), and nontraumatic surgical indications. Though we studied some but not all of these variables.

The finding of our study was found to have significant protective effect of topical vancomycin against SSI. With all surgeries undergone we had SSI in 1.93% (p = <0.001) of emergency surgeries, where Vancomycin powder was not used. There were no surgical site infection in any of the cases where topical Vancomycin powder was used. This correlates with the study findings of McCutcheon BA et al, where they found significant protection against SSIs (OR: 0.33; CI: 0.18-0.60), with the use of vancomycin powder after cranial operation. Similarly Chang SM et al pointed out statistically significant reduction in SSIs from 5% to 1.4% after cranial surgeries. Those studies pointed out these findings to be novel without having been previously investigated or described by other metaanalysis. However with limited number of surgeries, our rate of SSIs in NVG, 2.6%, along with the studies by afore mentioned authors in NVG is relatively high compared to current literature.

The costs of SSI are high in terms of both morbidity and hospital expense. Deep cranial wound infections may compromise the bone flap, dura, and brain and necessitate additional surgeries and prolonged antibiotic use. In severe cases, SSI may lead to abscess and death. If we calculate in financial prospect, definitely there has been reduction in total health care cost as there has been reduction in hospital stay. Beyond the direct costs of treatment, lost wages and economic productivity compound the financial impact. Also there has been no financial burden to the patient for further management of infection. Ravikumar V et al in their study approved this fact that use of Vancomycin being associated with reduction of healthcare costs. In this way, this intervention may also provide indirect financial gains from increased reimbursement with lower SSI rates.

Being retrospective study, there definitely is need of prospective study with inclusion of more number of cases. In this respect, this study is similar to large number of spinal studies that examined vancomycin efficacy.
Similarly, this study could have been specific if there has been correlation of the final outcome to the comorbidities that patient had, indication of the surgeries, diagnosis, etc. Here we couldn't deny the possibility that patient-related factors, indications and diagnosis, may influence infection risk. With prospective study we could definitely be able to compare the total cost that a patient has benefitted by not having, thus preventable SSI. The decision on using intrawound vancomycin was based on the surgeon’s preference and was not decided in prior. This is a multi-surgeon single-center study; the rate of SSI and type of organisms might differ based on the geographical location, surgeons practice, and patient-specific factors.

Additionally, this study utilized a surgery-centered analysis, in which each surgery was analyzed as a single event regardless of whether a patient underwent multiple surgeries. This approach was taken since utilization of topical vancomycin was dependent on each individual surgery and not each individual patient. Similarly, here is always a chance of unreported infections or complications from patients being seen at outside institutions. However, findings of this present study has encouraged us to proceed with further study to proceed prospectively, thus including detail variables like length of hospital stay, duration of surgery, confounding factors that could have led to infection, etc.

**Conclusion:**

This study has given the positive information for vancomycin use in cranial surgery thus significantly decreasing SSIs. There has been need of more prospective, larger, randomized, longer follow-up studies for more reliable result. There is insufficient evidence to suggest that routine single-use vancomycin powder leads to antibiotic resistance. Routine use of vancomycin powder as a surgical adjunct is supported by the available literature and warrants further examination in randomized controlled trials. We hypothesize that topical vancomycin use reduces infection rates by directly affecting any local inoculum at the time of surgery. A randomized prospective trial is warranted.

**References**